AIT-101 clears toxic protein clumps, early data show
AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral…
Articles by Marisa Wexler, MS
Expanded access program for SLS-005 begins treating first ALS patient
An expanded access program for the experimental treatment SLS-005 has dosed its first participant, according to…
Study links abnormal RNA modifications to TDP-43 function
TDP-43, a protein that is known to have toxic effects in amyotrophic lateral sclerosis (ALS), is able to interact…
MDA 2023: Issues with ALS scale scores noted in NurOwn trial failure
Difficulties in measuring the progression of amyotrophic lateral sclerosis (ALS) among patients with advanced disease can cause complications in…
MDA 2023: Designer DNA drug for ALS shows promise in mouse studies
In most cases of amyotrophic lateral sclerosis (ALS), dysfunction of a protein known as TDP-43 leads to abnormally low…
MDA 2023: Patients typically need wheelchairs within 2 years of onset
On average, a person with amyotrophic lateral sclerosis (ALS) will require a wheelchair to get around within two years…
FDA panel votes in favor of tofersen biomarker data
Changes in neurofilament light chain (NfL) levels — a biomarker of nerve cell damage — were deemed by an advisory…
MDA 2023: Expansion in WDR7 gene linked to increased ALS risk
A potential new genetic risk factor for amyotrophic lateral sclerosis (ALS) has been discovered by researchers at the University…
MDA 2023: COYA 302 therapy slows ALS progression in early trial
Four people with amyotrophic lateral sclerosis (ALS) each experienced a marked slowing in disease progression with COYA 302, an…
MDA 2023: Walking, other functions retained longer on Radicava
Amyotrophic lateral sclerosis (ALS) patients treated with Radicava (edaravone) tend to go longer before reaching disease milestones such…